Treating Lipodystrophy
Lipodystrophy has no cure, but its complications can be managed. For some patients, significantly improved. This page explains the main treatment approaches, what to monitor, and where the science is heading.
Treatment Goals
Lipodystrophy results from genetic or acquired dysfunction of adipose tissue, and no current therapy reliably reverses the underlying fat loss. Management should therefore focus on identifying and treating associated metabolic complications, including insulin resistance, diabetes, hypertriglyceridemia, hepatic steatosis, and cardiovascular risk, while monitoring and protecting organs at greatest risk for long-term morbidity and supporting patients’ quality of life.
01
Optimize glycemic control
Severe insulin resistance can make glycemic management challenging. Treatment should aim to reduce hyperglycemia and prevent microvascular complications, including neuropathy, nephropathy, and retinopathy.
02
Lower triglyceride levels
Marked hypertriglyceridemia increases the risk of acute pancreatitis and may require urgent intervention. Triglyceride reduction is often a key early treatment priority.
03
Monitor and protect liver health
Metabolic dysfunction–associated steatotic liver disease (MASLD), including progression to fibrosis or cirrhosis, is common in lipodystrophy. Ongoing liver assessment and optimization of metabolic control are central to management.
04
Reduce cardiovascular risk
Insulin resistance, hypertriglyceridemia, low HDL cholesterol, hypertension, genetic disposition and other features of metabolic syndrome contribute to elevated cardiovascular risk. Long-term care should include comprehensive cardiometabolic risk assessment and management.
05
Support reproductive and hormonal health
In women, severe insulin resistance may contribute to hyperandrogenism, menstrual irregularity, polycystic ovary syndrome–like features, and impaired fertility, particularly in familial partial lipodystrophy. Improving metabolic control may support hormonal and reproductive health.
06
Address quality of life and psychosocial burden
Fatigue, hyperphagia, body image concerns, anxiety, depression, and social burden should be assessed alongside metabolic parameters. Management should incorporate patient-centered interventions that support physical, emotional, and functional well-being.
Multidisciplinary care
Most patients with lipodystrophy benefit from coordinated specialist care, commonly involving endocrinology, cardiology, hepatology, dietetics, and, when indicated, nephrology, gynecology, genetics, and mental health support.
Medical Treatments
The medications used depend on the type of lipodystrophy, the severity of metabolic complications, and other health factors. Most patients require multiple medications and a change in nutrition and physical activity to be managed together.
Metreleptin (Myalepta / Myalept)
FDA & EMA Approved · The only disease-specific treatment
Disease-targeted leptin replacement therapy
Metreleptin is a recombinant leptin analogue used as adjunctive therapy to diet for selected patients with lipodystrophy and leptin deficiency. In the US, Myalept is approved for congenital or acquired generalized lipodystrophy; its safety and efficacy for partial lipodystrophy have not been established in the FDA label. In the EU, Myalepta is approved for generalized lipodystrophy from age 2 years and for selected partial lipodystrophy patients aged 12 years and above when standard treatments have failed.
Metreleptin addresses the hormonal consequences of adipose tissue deficiency but does not restore subcutaneous fat. In eligible patients, treatment may improve glycemic control, reduce triglycerides, lower insulin requirements, and support improvement in ectopic lipid burden, including hepatic metabolic disease. Access, eligibility criteria, and indication vary by country.
Managing diabetes and insulin resistance
All lipodystrophy subtypes
Insulin resistance in lipodystrophy can be profound and may exceed that typically seen in type 2 diabetes. Management often requires combination therapy, close monitoring, and escalation beyond standard first-line approaches. Poor glycemic control should be recognized as a consequence of the underlying adipose tissue disorder, ectopic lipid deposition, and relative or absolute leptin deficiency—not as non-adherence or therapeutic failure alone.
Insulin therapy
High-dose insulin therapy is frequently required to overcome severe insulin resistance. Concentrated insulin formulations or insulin pump therapy may be considered when injection volume, absorption, or adherence becomes challenging. Following initiation of metreleptin, insulin requirements may fall substantially, so glucose monitoring and proactive insulin dose adjustment are essential to reduce hypoglycemia risk.
Metformin
Metformin is commonly used to reduce hepatic glucose output and improve insulin sensitivity. It may help reduce insulin requirements and support broader metabolic control, although it is often insufficient as monotherapy in clinically significant lipodystrophy-associated diabetes.
GLP-1 receptor agonists / dual GIP–GLP-1 receptor agonists
GLP-1–based therapies may be considered to improve glycemic control, reduce appetite, support weight and metabolic management, and potentially improve triglyceride levels in selected patients. Their role should be individualized based on phenotype, nutritional status, gastrointestinal tolerability, and treatment goals.
SGLT2 inhibitors
SGLT2 inhibitors lower glucose independently of insulin by increasing urinary glucose excretion and may provide renal and cardiovascular benefit in appropriate patients. In lipodystrophy, they should be used cautiously, particularly in patients with severe insulin deficiency, low carbohydrate intake, acute illness, dehydration risk, renal impairment, or risk factors for ketoacidosis. Close monitoring and patient education are important.
Prevention of acute pancreatitis and reduction of cardiometabolic risk
Severe hypertriglyceridemia is common in lipodystrophy and may be profound, with levels exceeding 1,000 mg/dL in some patients. At this range, the immediate clinical priority is often prevention of acute pancreatitis, particularly when chylomicronemia is present. Management typically requires aggressive dietary intervention, optimization of glycemic control, and combination lipid-lowering therapy. Guidelines support pharmacologic therapy as an adjunct to diet and lifestyle for severe hypertriglyceridemia, with particular emphasis on pancreatitis prevention.
Low-fat diet
A low-fat diet is often required, particularly when triglycerides are markedly elevated or pancreatitis risk is high. Dietary management should be supervised by a clinician and dietitian familiar with lipodystrophy, as patients may also experience hyperphagia, diabetes, hepatic steatosis, and nutritional complexity.
Fibrates
Fibrates are commonly used as first-line pharmacologic therapy for severe hypertriglyceridemia and pancreatitis risk. They activate PPAR-alpha pathways, increasing triglyceride-rich lipoprotein clearance and reducing hepatic triglyceride production. In lipodystrophy, fibrates may substantially reduce triglycerides but are often insufficient as monotherapy.
Prescription omega-3 fatty acids
High-dose prescription omega-3 fatty acids may be used as adjunctive therapy to reduce hepatic triglyceride synthesis and enhance triglyceride clearance. They are often combined with fibrates or other lipid-lowering agents in patients with persistent severe hypertriglyceridemia.
Statins
Statins are used primarily for ASCVD risk reduction and LDL cholesterol lowering, rather than as primary therapy for severe triglyceride elevation. In patients with lipodystrophy, statin therapy should be considered based on the overall cardiovascular risk profile, including diabetes, hypertension, low HDL cholesterol, hypertriglyceridemia, and family history.
RNA-targeted therapies
RNA-targeted agents, including apoC-III–directed therapies, are emerging options for selected patients with severe genetic hypertriglyceridemia or familial chylomicronemia syndrome. These therapies reduce triglycerides by targeting proteins involved in triglyceride-rich lipoprotein metabolism. Their availability and indications vary by region, and they are generally not lipodystrophy-specific therapies; use should be considered in consultation with a lipid specialist. Volanesorsen is EMA-authorized for genetically confirmed familial chylomicronemia syndrome, while olezarsen was FDA-approved in 2024 for adults with familial chylomicronemia syndrome.
Diet and Lifestyle
Nutrition and physical activity
Nutrition is a central component of lipodystrophy management and should be individualized according to phenotype, metabolic complications, and treatment goals. Dietary recommendations may differ substantially from standard population-based healthy eating guidance, particularly in patients with severe hypertriglyceridemia, diabetes, hepatic steatosis, renal involvement, or hyperphagia.
Individualized medical nutrition therapy
There is no single dietary approach appropriate for all patients with lipodystrophy. Nutrition plans should be tailored based on lipodystrophy subtype, triglyceride levels, glycemic control, liver disease, kidney function, cardiovascular risk, medication regimen, and patient preferences. Common dietary patterns, including Mediterranean, ketogenic, very-low-carbohydrate, or high-protein diets, may not be appropriate for all patients and should be used cautiously when severe hypertriglyceridemia, hepatic disease, or renal impairment is present.
Specialist dietitian involvement
Patients should be referred to a registered dietitian nutritionist with expertise in complex metabolic disease, ideally with experience in lipodystrophy. Dietetic assessment should include review of laboratory trends, dietary intake, hunger and satiety patterns, pancreatitis risk, diabetes management, body composition concerns, and barriers to adherence. The goal is to develop a sustainable nutrition plan that supports triglyceride reduction, glycemic control, liver health, cardiovascular risk reduction, and quality of life.
Physical activity
Physical activity should be encouraged as tolerated and individualized to the patient’s metabolic status, cardiovascular risk, musculoskeletal limitations, and fatigue burden. Exercise may support insulin sensitivity, cardiometabolic health, functional capacity, and psychological well-being, but should be integrated alongside medical and nutritional management rather than treated as a standalone intervention.
Ongoing Care & Monitoring
Longitudinal surveillance and risk stratification
Because lipodystrophy affects multiple organ systems, ongoing monitoring is essential, including in clinically stable or asymptomatic patients. Metabolic, hepatic, renal, cardiovascular, skeletal, ophthalmologic, and psychosocial complications may develop progressively and may be clinically silent in early stages. Monitoring frequency should be individualized according to lipodystrophy subtype, disease severity, treatment regimen, metabolic stability, and patient-specific risk factors.
Patients should be encouraged to maintain copies of laboratory results, imaging reports, medication history, and key clinical summaries. Tracking longitudinal trends can support continuity of care, particularly when patients are evaluated by clinicians unfamiliar with lipodystrophy.
Recommended surveillance may include:
-
- Fasting triglycerides and full lipid panel
- HbA1c and fasting or continuous glucose assessment
- Liver function tests and hepatic imaging, when indicated
- Renal function, including eGFR and urine albumin/protein assessment
- Blood pressure monitoring and cardiovascular risk assessment, including ECG when appropriate
- Bone health assessment, including DEXA scan when clinically indicated
- Ophthalmologic examination for diabetic retinopathy in patients with diabetes
- Assessment of reproductive, endocrine, and nutritional status as appropriate
Mental Health & Wellbeing
Psychosocial burden and patient-centered care
The psychosocial impact of lipodystrophy is substantial and should be addressed as part of routine clinical care. As a rare, chronic, metabolically complex, and often visibly apparent condition, lipodystrophy can affect emotional wellbeing, body image, social functioning, family dynamics, treatment adherence, and overall quality of life.
Body image and identity
Changes in fat distribution, particularly involving the face, limbs, trunk, or musculature, may have significant psychological and social consequences. Patients may experience stigma, unwanted attention, misinterpretation of appearance, or distress related to body image. Referral to mental health professionals with experience in chronic illness, visible differences, or body image concerns should be considered.
Fatigue and functional burden
Chronic fatigue may reflect severe metabolic disease, insulin resistance, hepatic involvement, sleep disruption, treatment burden, or psychological distress. Fatigue should be assessed as a clinically relevant symptom rather than attributed solely to mood or behavior.
Hyperphagia and eating-related distress
Leptin deficiency may contribute to persistent hunger and hyperphagia. Clinicians should frame this as a biologically driven neuroendocrine symptom, not as a lack of discipline or poor adherence. Management should include education, dietetic support, family guidance, and, when appropriate, consideration of disease-specific therapy.
Navigating complex care
Patients often carry the burden of educating new clinicians about their diagnosis. Written care summaries, emergency plans, medication lists, and referral to specialist centers can reduce fragmentation and improve care coordination.
Children, adolescents, and families
Pediatric lipodystrophy affects the entire family system. Care plans may need to address school support, dietary management across the household, social challenges, growth and puberty, caregiver burden, and transition planning from pediatric to adult services.
Peer support and advocacy
Referral to patient organizations and peer-support communities can help reduce isolation, improve disease education, and support practical coping strategies. These resources may be particularly valuable for patients with rare conditions who have limited access to local expertise.
Clinical Trials and Research
Advancing evidence-based care in lipodystrophy
Patient participation in clinical research is essential to improving diagnosis, monitoring, and treatment options for lipodystrophy. Clinicians should discuss research opportunities with eligible patients, particularly when standard therapies are insufficient, access to disease-specific treatment is limited, or the patient is followed at a specialist center.
Clinical trial availability changes frequently, and eligibility depends on lipodystrophy subtype, age, metabolic status, prior treatments, leptin levels, comorbidities, and geographic location. Patients should be encouraged to review potential studies with their treating specialist before enrollment.
A live list of recruiting studies should be maintained rather than presented as static content. ClinicalTrials.gov remains a comprehensive registry for active and completed studies, and Lipodystrophy United also maintains a current clinical trials page with recruiting lipodystrophy studies and study contacts.
Below is a selection of featured ongoing trials.
Referral and care navigation
Connecting patients with specialist expertise
Patients with suspected or confirmed lipodystrophy should be referred to clinicians or centers with experience managing rare adipose tissue disorders and their metabolic complications. Lipodystrophy United maintains resources to help patients and healthcare professionals identify specialist centers, connect with research opportunities, and access peer support.
Clinicians can support patients by providing a clear diagnostic summary, relevant laboratory and imaging history, treatment history, and referral documentation to facilitate evaluation by specialist teams.
Our Impact
We have been working since 2012 to move the needle on the state of knowledge and treatments for the lipodystrophy community. Hit the button below to see a summary of just some of what we’ve been able to accomplish!
Clinical Signs
Does my patient have lipodystrophy?
Here’s what to look for.
Researchers & Clinicians
Home base for up-to-date clinical information regarding lipodystrophies.
Diagnosing Lipodystrophies
Home base for up-to-date diagnostic criteria and guidelines for managing lipodystrophy care.
Symptom Management
Many patients manage symptoms with their lifestyle and diet. Learn how they do it.
Fostering Unity and Collaboration with Our Dedicated Partners
